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Abstract. Counterfeit antimalarials (mainly artemisinin derivatives) is a crucial health problem in 
developing countries, particularly in Africa. The illegal production, sale and distribution of fake 
drugs is a huge market evaluated to several billion of dollars and represents more than 50% of the 
pharmaceutical market in several African countries. Fake drugs have led to a very great number of 
deaths  from  untreated  malaria  or  fatality  provoked  by  toxic  ingredients.  These fake  medicines 
increase  the  risk  of  artemisinin  resistance  developed  by  the  use  of  sub  therapeutic  dosages  of 
antimalarials. Tackling this criminal traffic is the objective of an international  program created by 
WHO  and involves the international police and custom organizations like INTERPOL. Several 
very important and encouraging results have been obtained, but the problem will be completely 
solved  if  genuine  antimalarials,  free-of-charge,  are  handed-over  to  populations  in  sub  Sahara 
African countries. 
For  decades,  counterfeiting  of  drugs  was  almost 
ignored or at least largely underestimated. It has now 
clearly  emerged  as  one  of  the  most  crucial  public 
health  problems  mainly  for  malaria  treatment  in 
developing      countries.
1,2,4,7,8  The  counterfeit  of 
antimalarial  drugs  at  first  received  little  attention 
compared  with  considerable  efforts  made  in  other 
aspects of malaria control. Although important efforts 
have been made to fight against this criminal traffic, 
much more needs to be done.  
It  is  interesting  to  note  that  during  the  past  
centuries,  poor  quality  drugs  have  been  a  persistent 
problem starting in the 1600s with fake cinchona bark 
and in the 1800s with fake quinine. The  problem  of 
modern-day  counterfeit  drugs  was  first  addressed  in 
1985  at  a  conference  in  Nairobi.  Unfortunately,  the 
counterfeit  market  continued  to  grow  and  has 
considerably spread all over the world  during the last 
decade, particularly in developing countries very often 
with the most dramatic consequences. This is largely 
the  result  of  the  wide-spread  use  of  the  internet  to 
market  counterfeit  products  in  an  unregulated 
environment  of  anonymity.  The  World  Health 
Organization (WHO) estimates that 50% of medicines 
available via internet are fake.  
On  the  whole,  counterfeiting  of  drugs  is  a  huge 
market estimated by WHO at more than US$35 billion 
and represents more than 15% of the pharmaceutical 
market worldwide with this proportion rising to more 
than  60%  in  developing  countries  (35-90%  in  south 
East  Asia).
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candidates for producers involved in this illegal trade 
mainly because the  benefits are immense and the risks 
very  limited  as  they  almost  always    prepare  large 
batches of  fake drugs  before disappearing and going 
elsewhere  to start-up  the same traffic all  over again. 
Fake  drugs  are  easily  transportable,  have  high  value 
per  unit,  and  above  all,  their  quality  cannot  be 
scientifically  or  legally  assessed  without  a  quality 
testing laboratory.  
Almost all kinds of medicines are counterfeited, but 
antimalarials  and  particularly  artemisinin  derivatives 
are  more  vulnerable    to  counterfeiting.  Until  now 
artemisinin  is  mainly  (if  not  only)  produced  in  Asia 
with  unfortunately    a  very  large  proportion  of  fake 
products.  According  to  an  account  of  the  Operation 
Jupiter  programme  published  in  the  open-access 
journal PLoS Medicine, 30 to 35% of bought artesunate 
are  counterfeit  in  South  East  Asia  (Thai-Myanmar 
border, Laos, Cambodia and Vietnam).
11 A report  was 
presented  by  Interpol  to  the  Chinese    Ministry  of 
Health  which  launched  a  criminal  investigation 
resulting in the arrest of a native of Yunnan province 
alleged to have bought 240 000 blisters of counterfeit 
artesunate.  
But  the  situation  is  even  more  dramatic  in  sub 
Saharan  Africa  where  the  burden  of  malaria  is  the 
greatest.  In  2001,  WHO  recommended  that  malaria-
endemic  African  countries  consider  changing  to 
artemisinin-derivatives, based of combination therapy 
(ACT) as first line treatment for malaria. This change 
has  gradually  been  implemented  (correct  as  recast?) 
during the past years, but adopting this new policy was 
not  easy  because  of  the  high  cost  of  ACT  and  the 
relative shortage of the raw plant material (Artemisia 
annua) from which artemisinin is extracted. Probably 
more  than  200  million  courses  of  ACT  are  annually 
used in Africa and the high cost and shortage of ACT 
provide    favorable  platforms  for  the  spread  of  fake 
artemisinin that can put the lives of many thousands 
African young children at risk. A large proportion of 
these fake antimalarials which are genuinely fake are 
imported  from  Asia.  There  is  also  a  thriving  fake 
antimalarial drug industry in some African countries, 
where  governments  promote  locally  produced 
antimalarials  which  are  not  always  counterfeited, 
stricto  sensu,  but  sub-standard  or  fake  drugs,  with  a 
name,  label,  packaging  different  from  that  of  the 
genuine products. 
Counterfeiting  is  more  than  a  criminal  act. 
Manslaughter
11 is perfectly justified to describe such an 
act although some prefer calling it simply  murder. It 
always  involves  unscrupulous    people  directing  a 
highly organized technical and sophisticated criminal 
trade.  These  criminals    make  tablets  out  of  starch, 
chalk, and a variety of wrong active ingredients for a 
life-threatening  disease  that  particularly  affects  the 
poor  populations  who  can  least  afford.  These 
perpetrators  knowingly  manufacture  these  fakes 
medicines  and  they  fully  know  that  their  ineffective 
product may kill people who would otherwise survive 
their malaria infection.  
In  counterfeit  products,  they  are  no  or  sub-
therapeutic  quantities  of  artemisinin  derivatives  and 
sometimes  contain  potentially  dangerous  substances 
such as metamizole (which may lead to bone marrow 
failure with agranulocytosis), melamine (which causes 
very severe and sometimes lethal urinary lithiasis) or 
safrole,  whose  hepatocarcinogenetic  action  was 
detected  in  1960–1961,  after  it  had  been  used  as  a 
flavoring agent for beverages  
The  full  extent  of  this  deceptive  yet  lucrative 
criminal  activity  is  not  well  known.  Figures  are 
underestimated and the consequences of this criminal 
activity certainly go beyond human boundaries.
8 Fake 
drugs  have  led  to  a  very  great  number  of  deaths 
(unfortunately impossible to know how many even by 
estimates or even to evaluate) from untreated malaria 
or  provoked  by  toxic  ingredients  as  these  fake 
medicines increase the risk of artemisinin resistance as 
a  result  of  the  use  of  sub  therapeutic  dosages  of 
antimalarials. 
But  some  other  important  consequences  of  the 
artemisinin counterfeiting are more indirect and often 
ignored  or  underestimated.  Fake  products  cause  the 
multiplication of false reports on artemisinin resistance 
and deplete the public's confidence in this vital drug 
and in the pharmaceutical industry.
9On the other hand, 
large  economic  losses  for  legitimate  manufacturers 
demotivates the pharmaceutical industry in producing 
tropical medicines, which is already by far not a top 
priority for this industry. 
The traffic of fake antimalarials is evidently linked 
to  the  dramatic  widespread  prevalence  of  malaria  in 
many  countries  and  the  need  for  an  affordable  and 
active  treatment.  But  officials  of    non-governmental 
organizations  (NGO’s),  international  agencies  or  aid 
organizations, through support of the Global Fund have 
initiated  some  incentives.  They  want  to  increase 
competition and lower the prices of medicines but they 
rarely  take  note  of  the  counterfeit  market  these 
incentives can encourage. After an active information 
campaign  during  the  past  years,  some  of  the 
associations  and  agencies  are  more  careful;  but  the 
problem still exists with small NGOs who have scant 
experience  of  the  health  and  economic  realities  in 
developing countries. 
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entirely dismantle this criminal market and to know the 
true  scale  of  the  issue.  In  recent  years,  increasing 
numbers  of  substandard  and  fake  medications  were 
detected  in  the  international  markets,  but  precise 
figures of the global situation are lacking, particularly 
in rural areas of Africa. Indeed, identical holograms, 
batch  numbers  and  expiry  dates,  and  blisters  and  
tablets looking absolutely genuine, make detection of 
fake  drugs  particularly difficult. Their packaging is 
always  a  perfect  copy  and  their  quality  cannot  be 
assessed  readily  by  lay  persons  or  even  experts  of 
pharmaceutical industry without  the aid of a quality 
testing laboratory. To check the product(s) inside the 
blisters,  many  techniques  were  proposed,  the  most 
precise  being  of  course  the  most  sophisticated  (for 
example,  the  innovative  high-performance  liquid 
chromatography  method,    two-dimensional  diffusion-
ordered  nuclear  magnetic  resonance  spectroscopy, 
combined  to  imaging  desorption  electrospray 
ionization  mass  spectrometry,  and  direct  analysis  in 
real-time  mass  spectrometry).
6,15,16  These  obviously 
require  laboratories  with  high  level  of  technical 
facilities  which  are  rarely  available  in  developing 
countries.  
But like seeing the ears of the hippopotamus, fake 
drugs  detection  is  only  the  first  step.  In  almost  all 
cases,  it  is  after  all  impossible  to  identify  the 
manufacturers except in exceptional situations  as was 
the case  in China, where a rare pollen specific in an 
area was detected by palynology
18 in fake artemisinins 
and  allowed the authorities to arrest those involved in 
this criminal activity. Very often even when the brain 
behind  this  lucrative  business  is  identified,  it  is 
generally  impossible  to  arrest  him  before  he  slips 
away. 
The  only  practical  possibility  is  to  act  at  the 
wholesale level and intercept and destroy fake drugs. 
Last year, 45 countries took part in an internet-based 
campaign  (operation PANGEA  III) involving  several 
international organizations, including police, customs, 
national drug regulators and internet service providers. 
These recent global enforcement efforts have led to the 
arrest of online  counterfeit sellers. However this action 
did not stem out supplies from illegal online sellers or 
keep them away from their creativity in illegally selling 
their products.  
Although  the  internet  plays  a  major  role  in  this 
traffic, it is not the only mean used by wholesalers. To  
tackle drugs counterfeiting other solutions have to be 
adopted in developing countries, mainly in Africa, at 
the  multinational  or  national  level.  Some  notable 
success  were  obtained,  for  example  in  Nigeria  by 
National  Agency for Food,  Drug  Administration and 
control  (NAFDAC)  or  mainly  thanks  to  an 
international  organization,  IMPACT  (International 
Medical  Products  Anti  Counterfeiting  Task  Force) 
created by WHO in 2008, closely with INTERPOL and 
involving a total of 193 countries. In East Africa, a sub 
program of IMPACT, (operation MAMBA)
13,14 led to 
the  to  arrest  several  manufacturers,  wholesalers  and 
retail  pharmacists.  It  also  allowed  the  seizure  of 
destruction  of  counterfeit  drugs  valued  at  several 
billion  of  dollars.  But  at  the  end  of  the  distribution 
chain,  it  is  difficult  and  almost  impossible  to  obtain 
significant  results  in  Africa,  where  counterfeit  drugs 
are often sold alongside vegetables in local markets or 
by hawkers (sidewalk markets) 
Tackling this network of criminal organizations at 
different levels is essential but not enough as it requires 
other approaches different from law enforcement and 
monitoring.  One  such  measure  could  involve 
increasing the availability of low priced genuine drugs 
–particularly  antimalarials  -  in  developing  countries. 
However, the risk is even with low prices, it will be 
easy for counterfeiters to produce and sell fake drugs at 
a much cheaper rate, because their main (if not only) 
expense is packaging.
10
Finally, the solution would be to give antimalarials 
completely  free  of  charge  to  developing  countries 
which  may  imply  a  huge  and  perhaps  unrealistic  
financial effort. 
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